DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/45rk9w/drg_insights) has announced the addition of Decision Resources, Inc's new report "DRG Insights: Multiple Myeloma (G7)" to their offering.
DRG Insights takes the most relevant information and insights from across our portfolio for BioPharma and Med-Tech products and delivers the insight heavy perspective that you need to generate better ideas and deliver more successful campaigns and initiatives.
The 2010 multiple myeloma (myeloma) market garnered impressive sales despite being a relatively small oncology indication in terms of incidence. Significant achievements in clinical practice over the last decade and the launches of efficacious, premium-priced agents drive market expansion, but untapped market potential remains for agents that can improve survival and reduce peripheral neuropathy and/or myelosuppression compared with currently available agents.
Key Topics Covered:
Current Market Landscape
Etiology & Pathophysiology
Select Drug Targets
Growth Drivers & Constraints
Key Metrics, Population Dynamics
Country Specific Decision Trees
Comparison of Key Agents
Expert Insight on Prescribing Trends
Importance of Drug Attributes in Prescribing Decisions
Pricing & Reimbursement
Factors Influencing Pharmacy Director Tier Placement Decisions
Accessibility and Cost Hurdles
Important Endpoints in Prescribing Decisions
2010 and 2010 sales and Market Share
For more information visit http://www.researchandmarkets.com/research/45rk9w/drg_insights.
Source: Decision Resources, Inc
Source: Research and Markets